Peptide reduced epileptic seizures in human brain tissue

Summary: The neuropeptide NPY reduces seizures in human brain tissue.

Source: Lund University

Researchers at Lund University in Sweden have used a neuropeptide to successfully reduce seizure-like activity in tissue from patients with drug-resistant epilepsy.

One challenge facing researchers who study brain diseases is that for understandable reasons it is difficult to obtain human brain tissue for experiments. For that reason, experimental models are used, such as rodent studies, but one problem is that these often cannot be directly translated to human conditions.

However, sometimes researchers get the opportunity to study donated brain tissue from patients who have undergone surgery for the treatment of epilepsy. The tissue can then be used to investigate if it is possible to affect the seizure-like activity, and try new treatments. However, this resected tissue rapidly loses its viability.

Just over a year ago, researchers at Lund University in Sweden developed a method that solves this problem, making it possible to keep and use human brain sections alive in a more standardised way. The result is that donated brain tissue can be studied for 48 hours, compared with the previous 12. This longer period means, among other things, that the researchers can study the effect of different gene therapy treatments on the tissue, and that more data is obtained from a small number of patients.

“This provides a unique opportunity to test new treatments, as we get so close to the actual condition in the patient, without conducting the experiment directly on the patient”, says My Andersson, who leads a research team at the Epilepsy Centre at Lund University and who led the development of the method.

The researchers have now used this method to test a neuropeptide, NPY, which in previous rodent studies was shown to alleviate seizures in a drug-resistant variant model of epilepsy, a form of the disease that cannot be treated with available medicines.

“We saw that the neuropeptide also reduced seizures in human brain tissue, which is an important step forward”, says Merab Kokaia, professor and leader of the peptide study at Lund University.

The neuropeptide helps to maintain the balance, homeostasis, in the brain, which among other things means that the peptide is released during an epileptic seizure and can reduce it – acting like a circuit breaker.

“What we want to do now is to see if we can use gene therapy to insert an extra gene for the peptide in affected patients and thereby reduce the excitability that leads to the epileptic seizures”, explains Merab Kokaia.

This shows a head and lightening bolt
The neuropeptide helps to maintain the balance, homeostasis, in the brain, which among other things means that the peptide is released during an epileptic seizure and can reduce it – acting like a circuit breaker. Image is in the public domain.

The idea is to use viral vectors to deliver the gene for the neuropeptide in order to treat the area in which the epilepsy arises. The genetic material of the viruses is emptied and replaced with the gene that produces the neuropeptide. The researchers hope that these viral vectors can deliver the gene that produces the neuropeptide to the right place in the brain – a bit like a Trojan horse.

“There is still a long way to go before we know if it works well enough so that the peptide can be used as a treatment for drug-resistant patients, but as we have now seen that it works in human epileptic tissue and in gene therapy studies in animals, we have reason to continue working on this track”, says Merab Kokaia.

The method that enables the brain tissue to live longer could be used by other researchers to validate if other promising molecules have the same effect in human brain tissue as they have in laboratory tests.

“In this way, the tissue that researchers get access to, thanks to donations from epilepsy patients who have undergone surgical treatment, can be used to validate treatments established in other animal studies in which an effect against epileptic seizure has been observed. If positive results are also seen in human epileptic tissue, there is then a greater confidence for advancing towards the very expensive and extensive clinical studies”, concludes Merab Kokaia.

About this neuroscience research article

Lund University
Media Contacts:
Merab Kokaia – Lund University
Image Source:
The image is in the public domain.

Original Research: Open access
“Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in Epilepsy”. Merab Kokaia et al.
Molecular Therapy Methods & Clinical Development doi:10.1016/j.omtm.2019.09.004.


Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in Epilepsy

Gene therapy has been suggested as a plausible novel approach to achieve seizure control in patients with focal epilepsy that do not adequately respond to pharmacological treatment. We investigated the seizure-suppressant potential of combinatorial neuropeptide Y and Y2 receptor single vector gene therapy based on adeno-associated virus serotype 1 (AAV1) in rats. First, a dose-response study in the systemic kainate-induced acute seizure model was performed, whereby the 1012 genomic particles (gp)/mL titer of the vector was selected as an optimal concentration. Second, an efficacy study was performed in the intrahippocampal kainate chronic model of spontaneous recurrent seizures (SRSs), designed to reflect a likely clinical scenario, with magnetic resonance image (MRI)-guided focal unilateral administration of the vector in the hippocampus during the chronic stage of the disease. The efficacy study demonstrated a favorable outcome of the gene therapy, with a 31% responder rate (more than 50% reduction in SRS frequency) and 13% seizure-freedom rate, whereas no such effects were observed in the control animals. The inter-SRS and SRS cluster intervals were also significantly prolonged in the treated group compared to controls. In addition, the SRS duration was significantly reduced in the treated group but not in the controls. This study establishes the SRS-suppressant ability of the single vector combinatorial neuropeptide Y/Y2 receptor gene therapy in a clinically relevant chronic model of epilepsy.

Feel free to share this Neurology News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.